摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(tert-butyloxycarbonyl)-4-(piperidinyl)-6-chloro-1,4-dihydrobenzo[d][1,3]oxazin-2-one | 612545-93-4

中文名称
——
中文别名
——
英文名称
1-(tert-butyloxycarbonyl)-4-(piperidinyl)-6-chloro-1,4-dihydrobenzo[d][1,3]oxazin-2-one
英文别名
1-(1-tert-butyloxycarbonyl-4-piperidinyl)-6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-one;tert-butyl 4-(6-chloro-2-oxo-4H-3,1-benzoxazin-1-yl)piperidine-1-carboxylate
1-(tert-butyloxycarbonyl)-4-(piperidinyl)-6-chloro-1,4-dihydrobenzo[d][1,3]oxazin-2-one化学式
CAS
612545-93-4
化学式
C18H23ClN2O4
mdl
——
分子量
366.845
InChiKey
PIDHNVVHJDBAAL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    177-179 °C(Solv: ethyl ether (60-29-7))
  • 沸点:
    487.7±45.0 °C(Predicted)
  • 密度:
    1.286±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    59.1
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Benzoxazinone-derived compounds, their preparation and use as medicaments
    申请人:——
    公开号:US20040058920A1
    公开(公告)日:2004-03-25
    The present invention relates to Benzoxazinone-derived compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals.
    本发明涉及一般式(I)的苯并噁唑酮衍生物,其制备方法,包含这些化合物的药物以及它们用于制备用于治疗人类或动物的药物的用途。
  • Benzoxazinone derivatives, their preparation and use as medicaments
    申请人:——
    公开号:US20040067941A1
    公开(公告)日:2004-04-08
    The present invention relates to new compounds of general formula (I), as well as to their physiologically acceptable salts, the procedures for their preparation, the intermediate compounds for obtaining them, the application of the compounds of general formula (I) as medicaments in the prevention and treatment of disorders of the Central nervous System and to the pharmaceutical compositions containing them. 1
    本发明涉及一般式(I)的新化合物,以及它们的生理可接受的盐,其制备方法,获得它们的中间化合物,将一般式(I)的化合物作为药物在预防和治疗中枢神经系统疾病方面的应用,以及包含它们的制药组合物。
  • Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity
    申请人:Torrens Jover Antoni
    公开号:US20070009597A1
    公开(公告)日:2007-01-11
    The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT 6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.
    本发明涉及一种活性物质组合,包括至少一种具有神经肽Y受体亲和力的化合物,优选为神经肽Y5受体亲和力,以及至少一种具有5-HT6受体亲和力的化合物,一种包含该活性物质组合的药物,以及使用该活性物质组合制造药物。
  • Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments
    申请人:Torrens Jover Antoni
    公开号:US20070032482A1
    公开(公告)日:2007-02-08
    The present invention relates to benzoxazinone-derived sulphonamide compounds of general formula (I), a process for their preparation, a medicament comprising these compounds and the use of benzoxazinone-derived sulphonamide compounds for the preparation of medicaments for 5-HT 6 receptor regulation as well as for the treatment of disorders related thereto.
    本发明涉及一般式(I)的苯并噁唑酮衍生磺酰胺化合物,其制备过程,包含这些化合物的药物以及苯并噁唑酮衍生磺酰胺化合物用于制备5-HT6受体调节剂药物以及治疗与之相关的疾病。
  • ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY
    申请人:Torrens Jover Antoni
    公开号:US20120128768A1
    公开(公告)日:2012-05-24
    The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity and at least one compound with 5-HT6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.
    本发明涉及一种活性物质组合物,包括至少一种具有神经肽Y受体亲和力的化合物和至少一种具有5-HT6受体亲和力的化合物,以及包含该活性物质组合物的药物和使用该活性物质组合物制造药物的用途。
查看更多